Open house Arzneimittelrabattverträge Febuxostat, ATC M04AA03
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Febuxostat, ATC M04AA03
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed revenue; actual sales depend on prescription volumes and competition.
Contract may be automatically terminated if a regular framework agreement for the same active ingredient comes into eff...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2026
- Signing non-exclusive discount agreements for Febuxostat (ATC M04AA03) with AOK Bayern.
- Adherence to standardized contract terms and conditions.
Show full summary
Open house model for non-exclusive pharmaceutical discount agreements on Febuxostat (ATC M04AA03) offered by AOK Bayern to all interested pharmaceutical companies. No competitive selection; any eligible company can join under standardized terms. Contracts run from 01.10.2024 to 30.09.2026, with applications accepted until 05.08.2026.
Risks
No guaranteed revenue; actual sales depend on prescription volumes and competition.
Contract may be automatically terminated if a regular framework agreement for the same active ingredient comes into eff...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible.
Administrative
- Submission of a signed self-declaration of reliability.
- Contract must be submitted in two original copies if in paper form.
Requirements may be incomplete.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Febuxostat, ATC M04AA03
Non-exclusive discount agreements for the active ingredient Febuxostat. All interested pharmaceutical companies meeting eligibility can sign identical, non-negotiable contracts. Place of performance: Munich, Germany.
Location
Duration
Category
Deadline
Award details
Selection criteria
Value note
Show original TED data
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 15 Aug 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 491622-2024
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed revenue; actual sales depend on prescription volumes and competition.
Contract may be automatically terminated if a regular framework agreement for the same active ingredient comes into eff...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications